Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Meeting Calendar
  3. Past Meetings
  4. ESMO Congress 2024
  5. Satellite Symposia Webcasts

Novartis - Radioligand therapy for advanced prostate cancer: are we on target?

Who should we treat? Optimizing the impact of RLT in patients with metastatic castration resistant prostate cancer

Date

16 Sep 2024

Session

Novartis - Radioligand therapy for advanced prostate cancer: are we on target?

Topics

Radiation Oncology

Tumour Site

Prostate Cancer

Presenters

Kim Nguyen Chi, Matthias Eiber, Joan Carles Galceran, Jochen Walz

Authors

K.N. Chi1, M. Eiber2, J.C. Galceran3, J. Walz4

Author affiliations

  • 1 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 2 TUM - Technical University of Munich, 80333 - Munich/DE
  • 3 Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 4 IPC - Institut Paoli-Calmettes, 13273 - Marseille, Cedex 09/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Kim Nguyen Chi

Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?

Resources:

Webcast

Closing remarks

Presenter: Kim Nguyen Chi

Session: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.